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Abstract
Background: Cardiovascular disease has been linked to endothelial progenitor cell (EPC) depletion and functional
impairment in atherosclerosis and aortic stenosis. EPCs may play a pivotal role in vascular grafting. However, the
EPC depletion in coronary artery bypass grafting (CABG) patients has not been compared to coronary artery
disease-free valvular replacement patients with aortic stenosis.
Methods: We aimed to assess the basal number of CD34+/KDR+ and CD34+/CD144+ cells in CABG patients,
compared to aortic stenosis valvular replacement patients. 100 patients (51 CABG and 49 valvular surgery ones)
were included in the present study. All CABG or valvular patients had angiographic demonstration of the presence
or the absence of coronary artery disease, respectively. Numbers of CD34+/KDR+ and CD34+/CD144+ were assessed
by flow cytometry of pre-surgical blood samples.
Results: We found a lower number of CD34+/CD144+ cells in CABG patients compared to valvular patients (0.21 ±
0.03% vs. 0.47 ± 0.08%), and this difference remained statistically significant after the P was adjusted for multiple
comparisons (P = 0.01428). Both groups had more EPCs than healthy controls.
Conclusions: Pre-surgical CD34+/CD144+ numbers are decreased in CABG patients, compared to valvular patients
with absence of coronary disease.
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1. Background
Atherothrombosis is the leading global cause of morbi-
mortality [1]. A growing burden of experimental and clini-
cal evidence highlights the importance of endothelial
progenitor cells (EPCs) in the pathogenesis of this disease
[2,3]. EPCs originate in the bone marrow and migrate in
response to ischemic stimuli, especially stromal-derived
factor (SDF-1) [4]; they differentiate towards the endothe-
lial lineage or support local angiogenesis by resident
endothelial cells. In their differentiation process, EPCs
possess the early markers CD34 and KDR and acquire
further markers of endothelial commitment (such as
CD144, also known as VE-cadherin) [2].
Several studies describe a lower number of CD34+/KDR+
cells in patients with coronary artery disease (CAD); these
low numbers seem to be inversely correlated with cardio-
vascular risk factors [4]; moreover, this EPC decrease has
been directly linked to CAD [5] and to precede future car-
diovascular events [6]. Lower CD34+/CD144+ numbers
have been described in atherosclerotic patients, as well
as the role of statins to differentiate CD34+/KDR+ to
CD34+/CD144+ [7].
Other reports, however, suggest a higher number of
EPCs in atherosclerosis [8]. A population-based study
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shows a direct correlation between CD34+/KDR+ and
Framingham risk factors [9]. In addition, long-term statin
treatment has been related to a reduced number of
CD34+/KDR+ in patients with CAD [10]. This discrepancy
may be explained by the possible oscillation of cell number
depending on the vascular disease state, which depends on
the intensity of the ischemia [11]. Higher apoptosis and
lower viability have been observed in cultured EPCs from
atherosclerotic patients, especially diabetics [12,13]. High
glucose concentrations impair adhesive properties of EPCs
under flow conditions [14]. The recent clinical evidence
suggests a role of bone marrow-origin EPC exhaustion in
advanced atheroscelrotic cardiovascular disease [15]. How-
ever, EPC exhaustion has equally been described in degen-
erative aortic stenosis and it may mediate endothelial
damage in this disorder [16]. Both CABG and valvular
replacement surgery dramatically increase the number of
EPCs, however these EPCs seem to be functionally
impaired after both interventions [17]. The question arises
whether CABG with advanced atherosclerotic disease and
valvular replacement patients with aortic stenosis and
angiographic abscence of coronary lessions possess differ-
ent EPC levels. Thus, we aimed to assess the number of
CD34+/CD144+ and CD34+/KDR+ cells in the peripheral
blood of patients undergoing coronary artery bypass graft-
ing (CABG) with angiographic demonstration of CAD,
compared to valvular surgery patients with angiographic
demonstration of absence of CAD. The ultimate goal was
to elucidate which vascular disorder involves a deeper
alteration of EPC numbers.
2. Methods
2.1. Clinical research design
Patients were recruited from the Service of Cardiac Sur-
gery (Hospital Clinico San Carlos, Madrid, Spain). Coron-
ary angiography was performed in all the patients before
inclusion in each group. Included valvular patients had
aortic stenosis and abscence of significant coronary steno-
sis. Patients who suffered CAD and aortic stenotic valvular
disease and were operated for both diseases at the same
time were equally a priori excluded, since we aimed to
compare ischemic patients with the angiographically pro-
ven presence or absence of coronary artery disease. The
study was designed for pre-surgical blood samples. Thus,
for logistic disposability of the flow cytometer, consecutive
CABG or valvular patients were included once a week,
given that the cytometer was reserved every Monday. The
n (minimum of 45 per group) was calculated based on the
variability of EPC number in a cohort of healthy subjects
where this parameter was assessed by using the same
laboratory protocol and flow cytometer [18]. These num-
bers of patients were recruited from May 2007 to May
2009. Exclusion criteria were: end-stage renal or liver dis-
ease, previous heart surgery, absence of coronariography,
cancer and autoimmune disease. The study was approved
by the local Ethical Committee and was conducted accord-
ing to the declaration of Helsinki. All patients gave written
informed consent. As a comparative healthy control
group, we included 27 healthy volunteers from the Bosch
Company (Madrid, Spain). For this healthy cohort, all car-
diovascular risk factors (smoking, obesity, hypertension,
hypercholesterolemia, diabetes and physical inactivity)
were considered as exclusion criteria.
2.2. Basal characteristics of the study groups
The primary objective of the study was to compare the
number of CD34+/KDR+ and CD34+/CD144+ cells in the
pre-surgical blood of CABG and aortic stenosis valvular
patients, respectively. However, in addition to coronary
obstruction [5], other parameters have been shown to
affect EPC number: age, sex, body mass index, smoking,
alcohol, dyslipidemia, diabetes, antiplatelet drugs, antihy-
pertensive, antidiabetic, hypolipidemic drugs [10] and
euroSCORE cardiac surgery risk stratification [19]. There-
fore, they were also compared between both groups and
taken into account for the statistical analysisis. The euro-
SCORE was calculated as a logistic index.
2.3. Definitions
Diabetes mellitus was defined according to the criteria of
the American Diabetes Association as fastin serum glucose
above 126 mg/dl, or the use of antidiabetic drugs. Dyslipi-
demia was defined as fasting total serum cholesterol
> 200 mg/dl, LDL > 100 mg/dl, triglycerides > 180 mg/dl,
or the use of lipid-lowering therapy. Myocardial infarction
was defined as a transient increase of specific serum mar-
kers of myocardial necrosis (CK-MB or troponin T) along
with ischemic symptons and/or typical electrocardio-
graphic signs. A coronary vessel was considered as
obstructed if luminal obstruction reached 50% (for the
main trunk coronary artery) or 75% (for any of the three
principal vessels).
2.4. Blood collection and flow cytometry
Percentage of CD34+/KDR+ and CD34+/CD144+ cells was
assessed as described [18]. Blood was taken before the sur-
gical procedure using EDTA-Vacutainer® tubes. Immu-
nostaining was performed immediately. Briefly, 10 μl of
respective antibodies were added to each 100 μl of ali-
quoted blood: mouse IgG1k isotype control fluorescein iso-
thiocyanate conjugated (555748, Becton Dickinson,
Franklin Lakes, NJ, USA), mouse IgG1 isotype control phy-
coerythrin conjugated (IC002P, R&D Systems, Minneapo-
lis, MN, USA), mouse IgG2B isotype control phycoerythrin
conjugated (IC0041P, R&D Systems), mouse IgG1k anti-
CD34 isothiocyanate fluorescein conjugated (555821,
Becton Dickinson), mouse IgG1 anti-VEGF-R2 (KDR),
phycoerythrin conjugated (FAB357P, R&D Systems) and
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mouse IgG2B anti-CD144 (VE-cadherin) phycoerythrin
conjugated (FAB9381P, R&D Systems). The blood was
incubated for 30 min on ice protected from the light. Red
blood cells were lysed by a commercial lysis solution
(347691-MSDS-A, Becton Dickinson) for 10 minutes at
room temperature. This lysis buffer also acts a smooth
fixative. Samples were kept at 4°C protected from the light
and cytometric analysis was made within the next 24
hours, which yields a high intra-assay correlation com-
pared to fresh analysis (r2 = 0.8517). This analysis was per-
formed using a FACScalibur flow cytometer (Serial
Number E2295, BD, San Jose, CA, USA). Mononuclear
cells were selected for the analysis. The events were
plotted as linear SSC/FSC and the beams lower left (con-
sidered as lymphocytes), and immediately upper right
(considered as monocytes) were gated for the analysis,
whereas polymorphonuclear cells (with a higher size and
complexity) were discarded. A representative gating strat-
egy is shown in Figure 1, panel A. Cytometry technicians
were unaware of each patient data group. Analysis was
performed using CellQuestPro®. Briefly, the quadrants
were defined according to the control IgG (the region
where positive events were not counted) and they were
exported for the analysis of the next two experimental
samples (CD34+/KDR+ and CD34+/CD144+). Therefore,
the positive CD34+/KDR+ and CD34+/CD144+ events
were noted in a region where no event were detected in
the control IgG sample. Representative cytometry profiles
are shown in Figure 1, panels B, C and D.
2.5. Determination of plasmatic concentration of
cytokines
Blood from EDTA tubes was centrifuged at 1500 rpm
for 15 minutes. Plasma was extracted and frozen at -40°
C. Total levels of TGF-b1 (active plus acid-activatable)
were assessed by ELISA (R&D Systems, Minneapolis,
MN, USA). This kit proved highly reproducible in a
large comparative study of several ELISA kits for TGF-b
[20]. Plasma levels of IL-6 and TNF-a were assessed by
ELISA (Minneapolis, MN, USA), given that these cyto-
kines have been proven to be deeply altered in cardiac
surgery [21]. SDF-1 concentration was measured by
ELISA (R&D systems, Minneapolis, MN, USA) from pla-
telet-poor plasma, following the manufacturer’s
instructions.
2.6. Statistics
Data are reported as mean and standard error of the
mean (SEM) for continuous variables. Normality was
assessed by the Shapiro-Wilk test. Comparison and cor-
relation analyses were performed with Student T-test
and Pearson coefficient correlation or the correspondent
non-parametric tests. Analysis of variance (ANOVA)
was used to test for differences in means across treat-
ment groups, and with significant differences a post hoc
HSD-Tukey test was used to compare specific treatment
groups. Differences with a P value of less than 0.05 were
considered statistically significant. Multivariate regres-
sion analysis was performed between the primary vari-
able versus all clinical variables. The Bonferroni test was
used for multiple comparisons. Analyses were conducted
with the program R, version 2.0.1 (Institute for Statistics
and Mathematics, Wirtschaftsuniversität Wien, Vienna,
Austria).
3. Results
3.1. Clinical and laboratory profile of the patients
Following the recruitment protocol stated in Methods,
54 patients operated for CABG and 53 patients operated
for aortic stenosis valvular replacement surgery were
enrolled for the present study. 3 CABG and 4 valvular
patients were excluded, since the second review of their
clinical report revealed that they had one or more exclu-
sion criteria after their pre-surgical EPC number was
already assessed. This yielded 51 CABG and 49 valvular
patients. A flow diagram of the patients is shown in the
Figure 2.
As shown in Table 1, CABG patients possessed a sig-
nificantly higher burden of cardiovascular risk factors
(diabetes and dyslipidemia) and medications (antiplatelet
drugs, statins, nitrates, oral antidiabetics and insulin).
They had lower left ventricular ejection fraction, higher
rate of myocardial infarction within 30 days before sur-
gery and a lower logistic euroSCORE risk assessment.
This last finding may be explained by the higher mean
age and female/male ratio in the valvular group, despite
a lower incidence of previous myocardial infarction
(Table 1). Given that our hospital is a reference center
for cardiac surgery, no data were available for HDL cho-
lesterol and quantification of angina symptoms.
CABG had a significant increase of platelets, mono-
cytes and fibrinogen. Plasmatic levels of TGF-b1, SDF-1,
IL-6 and TNF-a remained unchanged, suggesting that
none of these plasma markers were specific for angio-
graphic coronary obstruction (Table 2).
In the control cardiovascular risk factor-free group
(with absence of angiographic study for ethical reasons),
the mean age was 42.78 ± 1.969 (mean ± SEM) and the
percentage of women was 35.71%.
3.2. CD34+/KDR+ and CD34+/CD144+ numbers
As shown in Figure 3, panel A, CABG and aortic steno-
sis valvular patients did not possess a significantly differ-
ent level of CD34+/KDR+ cells, although a decreasing
trend was noted for CABG. Figure 3, panel B shows the
numbers of CD34+/CD144+ cells. Patients ongoing
Redondo et al. Journal of Cardiothoracic Surgery 2012, 7:2
http://www.cardiothoracicsurgery.org/content/7/1/2
Page 3 of 9
CABG had a lower number of CD34+/CD144+ cells
compared to valvular surgery patients, in a significant
manner. The total numbers of CD34+/KDR+ and
CD34+/CD144+ per μl were equally assessed. As shown
in the Table 2, yet again the total number of CD34+/
CD144+ per μl remained lower in the valvualr group
compared to the patients who underwent CABG,
whereas CD34+/KDR+ remained unchanged. Both
groups of patients had higher numbers of CD34+/
CD144+ cells compared to healthy volunteers without
cardiovascular risk factors (Figure 3).
In a subgroup of aortic stenosis valvular patients where
echocardiac valvular gradient (mmHg) and valvular area
(cm2) were available, there was not a significant correla-
tion among these parameters and the abundance of
CD34+/CD144+ (r2 = 0.021, P = 0.41 for mean gradient
and r2 = 0.015 and P = 0.48 for valve area, respectively).
3.3. Effects of clinical and laboratory parameters on
CD34+/CD144+ numbers
In order to explore whether the different numbers of
CD34+/CD144+ may be mediated by different clinical
and analytical parameters between CABG and aortic
stenosis valvular patients, intragroup analysis using
these parameters were made. As shown in Table 3, in
the CABG group only the presence of dyslipidemia
was associated to decreased CD34+/CD144+ counts.
This suggests that the clinical and laboratory differ-
ences between CABG and valvular patients (Tables 1
and 2) are not responsible of the different numbers
of CD34+/CD144+ cells between these two groups.
However, in these non-primary endpoints the P
values were not adjusted to the number of compari-
sons and thus should be interpreted in an exploratory
manner.
Figure 1 Percentage of double-positive cells in peripheral blood or cell culture samples. Panel A: Representative gating strategy. Panel B:
Representative cytometry profile for control IgG. Panel C: Representative cytometry profile for CD34+/KDR+. Panel D: Representative cytometry
profile for CD34+/CD144+.
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3.4. Multivariate analysis
We performed a multivariate analysis and the P values
were adjusted to the number of comparisons. As shown
in the Table 4, being CABG or valvular yields a signifi-
cant association with CD34+/CD144+ cell numbers after
this analysis was performed (P = 0.01428 after Bonfer-
roni adjustment).
4. Discussion
Our results show a lower basal number of CD34+/CD144+
cells in the pre-surgical blood of patients who underwent
CABG surgery compared to aortic stenosis valvular repla-
cement patients (Figure 3, panel B). Of note, being CABG
or valvular was related to CD34+/CD144+ cells even after
the P value was adjusted to the number of comparisons
Figure 2 Flow diagram of the patients. After all clinical exclusions, 51 patients operated for coronary artery bypass grafting and 49 patients
operated for valvular replacement (aortic stenosis) were chosen for the present study.
Table 1 Clinical and pharmacological characteristics of
the patients.
CABG Valvular P
Number 51 49 -
Age 64.65 ± 13.34 72.7 ± 10.4 0.106¶
Sex (Women, %) 8 (15.69%) 22 (44.89%) 0.001*
BMI (kg/m2) 26.91 ± 0.43 26.51 ± 0.57 0.5726§
EF (%) 62.51 ± 1.84 69.2 ± 1.41 0.006§
Tobacco 12 (23.53%) 9 (18.37%) 0.698*
Alcohol intake 15 (29.41%) 14 (28.57%) 0.898*
Hypertension 31 (60.78%) 27 (55.10%) 0.486*
Dyslipidemia 31 (60.78%) 16 (32.65%) 0.003*
Diabetes 24 (47.06%) 5 (10.20%) < 0.001*
ACEI/ARB 25 (49.02%) 19 (38.77%) 0.302*
Beta blockers 16 (31.37%) 9 (18.37%) 0.133*
Calcium blockers 8 (15.69%) 10 (20.41%) 0.539*
Antiplatelet drugs 33 (64.71%) 8 (16.33%) < 0.001*
Statins 34 (66.67%) 11 (22.45%) < 0.001*
Nitrates 16 (31.37%) 2 (4.08%) < 0.001*
Oral antidiabetics 16 (31.37%) 2 (4.08%) < 0.001*
Insulin 13 (25.49%) 1 (2.04%) < 0.001*
MI < 30 days 16 (31.37%) 0 (0%) < 0.001*
EuroSCORE 3.6 ± 0.4194 5.7 ± 0.4 < 0.001*
* = Chi-squared test, § = Student’s t test, ¶ = U Mann-Whiney-Wilcoxon test
BMI: body mass index; EF: ejection fraction; MI; myocardial infarction
Table 2 Biochemical and hematological data.
CABG Valvular P
Number 51 49 -
Glucose 108.2 ± 5.12 108.9 ± 6.56 0.4258¶
Creatinine 1.2 ± 0.049 1.154 ± 0.045 0.5003§
eGFR (ml/min/1.73) 70.24 ± 2.96 65.61 ± 2.96 0.2614
Platelets 240200 ± 94 211100 ± 83 0.0228§
Hemoglobin 13.09 ± 0.03 13.76 ± 0.03 0.0762§
Leucocytes 8255 ± 298 7525 ± 298 0.0871§
Neutrophils 4939 ± 225.6 4534 ± 319.9 0.3008§
Monocytes 689.6 ± 36.01 566.1 ± 28.20 0.0085§
Lymphocytes 2273 ± 109.8 2122 ± 125.3 0.3667§
Total CD34+/KDR+/μl 8.204 ± 4.01 7.347 ± 2.60 0.0952¶
Total CD34+/CD144+/μl 3.684 ± 0.70 7.694 ± 2.21 0.0217¶
Fibrinogen 484.4 ± 20.63 387.7 ± 11.07 < 0.0001§
TGF-b1 (ng/ml) 55.73 ± 3.55 52.48 ± 3.46 0.5144§
SDF-1 (ng/ml) 3.525 ± 0.11 3.604 ± 0.11 0.6152§
IL-6 (pg/ml) 3.152 ± 0.80 2.542 ± 0.29 0.4824§
TNF-a (pg/ml) 3.745 ± 0.55 4.099 ± 0.68 0.7216§
§ = Student’s t test, ¶ = U Mann-Whiney-Wilcoxon test
eFGR: Estimated glomerular filtration rate (ml/min/1.73 m)
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Figure 3 Abundance of CD34+/KDR+ and CD34+/CD144+ cells in the pre-surgical peripheral blood of the patients, and healthy
controls. Panel A: abundance of CD34+/KDR+ cells. Panel B: abundance of CD34+/CD144+ cells.
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(Table 4). This suggests that this parameter could be
related to angiographic CAD in severe and advanced car-
diovascular disease.
The clinical characteristics of our patients merit some
comments (Tables 1 and 2); although in these non-pri-
mary endpoints the P values were not adjusted to the
number of comparisons and thus should be interpreted
in an exploratory manner. CABG had a larger amount
of atherosclerotic risk factors and related medications
(Table 1) and higher numbers of monocytes, fibrinogen
and platelets (Table 2), which reproduces what was
found in other series [22]. This reinforces the broadly
accepted idea that atherosclerosis acts as an
inflammatory stimulus, a concept supported by the find-
ing of augmented CRP levels in a subgroup of our
CABG patients (3.4 ± 1.67 mg/l), In the intragroup ana-
lysis we found that only dyslipidemia had a significant
effect on CD34+/CD144+ numbers in CABG patients
(Table 3). Of note, the plasmatic concentration of sev-
eral cytokines (TGF-b1, SDF-1, IL-6 and TNF-a) in
CABG and valvular patients remained unchanged (Table
2). Therefore, these parameters were not specific enough
to discriminate between patients with angiographic pre-
sence or absence of coronary disease in our study.
The numbers of CD34+/CD144+ cells in the peripheral
blood of cardiac surgery patients (both CABG and valvu-
lar) is higher than reported elsewhere for CD34+/KDR+
[5,6], and than the one which was obtained by us in a
cohort of healthy volunteers [18]. A population-based
study shows that CD34+/KDR+ cells and SDF-1 levels are
directly associated with Framingham risk factors, whereas
this correlation becomes inverse when CD34+/KDR+ are
compared to vessel injury parameters such as intima-
media thickness [9]. Our results show that CD34+/KDR+
Table 3 Intragroup variation of CD34+/CD144+ according to different parameters
CABG Valvular
Sex Men: 0.2276 ± 0.03
Women: 0.1259 ± 0.05 (P = 0.13)¶
Men: 0.4189 ± 0.08
Women: 0.5423 ± 0.15 (P = 0.54)¶
EF (%) < Mean: 0.2492 ± 0.05
> Mean: 0.1722 ± 0.03 (P = 0.21)¶
< Mean:0.5375 ± 0.11
> Mean: 0.4419 ± 0.12 (P = 0.46)¶
Tobacco Yes: 0.1583 ± 0.05
No: 0.2300 ± 0.03 (P = 0.35)¶
Yes: 0.43 ± 0.12
No: 0.4835 ± 0.09 (P = 0.52)¶
Dyslipidemia Yes: 0.1542 ± 0.03
No: 0.3045 ± 0.05 (P = 0.016)¶
Yes: 0.3363 ± 0.08
No: 0.5412 ± 0.11 (P = 0.38)¶
Diabetes Yes: 0.2129 ± 0.05
No: 0.2133 ± 0.04 (P = 0.59)¶
Yes: 0.4160 ± 0.29
No: 0.4809 ± 0.08 (P = 0.43)¶
Antiplatelet drugs Yes: 0.2330 ± 0.04
No: 0.1767 ± 0.04 (P = 0.66)¶
Yes: 0.1925 ± 0.09
No: 0.5293 ± 0.09 (P = 0.0238)¶
Statins Yes: 0.1947 ± 0.03
No: 0.2500 ± 0.06 (P = 0.42)¶
Yes: 0.1925 ± 0.09
No: 0.5293 ± 0.09 (P = 0.02)¶
Nitrates Yes: 0.2856 ± 0.06
No: 0.1800 ± 0.03 (P = 0.21)¶
Yes: 0.4250 ± 0.20
No: 0.4767 ± 0.08 (P = 0.90)¶
Oral antidiabetics Yes: 0.1944 ± 0.05
No: 0.2217 ± 0.03 (P = 0.31)¶
Yes: 0.8950 ± 0.68
No: 0.4564 ± 0.08 (P = 0.28)¶
Insulin Yes: 0.2954 ± 0.07
No: 0.1850 ± 0.03 (P = 0.19)¶
Yes: 0.09 ± 0 (n = 1)
No: 0.4823 ± 0.08 (P < 0.0001)§
MI < 30 days Yes: 0.2481 ± 0.06
No: 0.1971 ± 0.03 (P = 0.37)¶
Yes: 0.4749 ± 0.08
No: 0 ± 0 (P < 0.0001)§
EuroSCORE Yes: 0.1852 ± 0.03
No: 0.2575 ± 0.06 (P = 0.46)¶
Yes: 0.4489 ± 0.16
No: 0.4890 ± 0.09 (P = 0.55)¶
Platelets Yes: 0.2403 ± 0.04
No: 0.1710 ± 0.04 (P = 0.27)¶
Yes: 0.3627 ± 0.07
No: 0.6004 ± 0.15 (P = 0.48)¶
Monocytes < Mean: 0.2015 ± 0.03
> Mean: 0.2252 ± 0.05 (P = 0.71)¶
< Mean: 0.4668 ± 0.13
> Mean: 0.4821 ± 0.09 (P = 0.48)¶
Fibrinogen < Mean: 0.2411 ± 0.05
> Mean: 0.1645 ± 0.05 (P = 0.09)¶
< Mean: 0.3945 ± 0.08
> Mean: 0.4700 ± 0.11 (P = 0.98)¶
§ = Student’s t test, ¶ = U Mann-Whiney-Wilcoxon test.
Table 4 Multivariate analysis (the P value was adjusted
to the number of comparisons by the Bonferroni test).
Estimate SEM P
CABG/Valvular -5.5532 2.2252 0.01428
ACEI/ARB 5.6474 2.3756 0.01942
Age -0.2615 0.0887 0.00402
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and CD34+/CD144+ from healthy subjects without athero-
sclerotic risk factors are clearly decreased compared to
ischemic non-atherosclerotic patients (Figure 3). Thus, our
data support the idea that EPCs are released in response to
ischemia and they reach different levels in CABG and valv-
ular patients. These findings agree with the emerging con-
cept that EPCs are released in response to ischemia, being
further depleted in advanced cardiovascular disease [9].
This may help to explain why several studies show that
these cells are reduced in cardiovascular disease [4-6],
whereas they are physiologically mobilized from the bone
marrow in response to ischemia [2,3]. The idea of EPC
exhaustion in atherosclerosis is supported by recent clini-
cal evidence [15]. However, in the present study this
decrease is found in a significant manner only for CD34
+/CD144+, not for CD34+/KDR+ (Figure 3). Given that
CD34+/CD144+ is considered as a more differentiated
EPC phenotype [7], it could be postulated that this
advanced differentiation may be disrupted in CABG
patients due to a longer history of atherosclerotic vascular
damage. Lower CD34+/KDR+ numbers for atherosclerotic
populations described elsewhere [6] were not assessed in
patients where CAD was angiographically demonstrated
and were candidates for surgical CABG. Our data also
show a lower number of CD34+/CD144+ cells despite a
higher rate of cardiovascular drug consumption (Table 1).
In the case of statins, the particular history of CABG
patients (long-term, severe and advanced angiographic
CAD) may also explain the lack of CD34+/KDR+ decrease
[10] and subsequent differentiation-related CD34
+/CD144+ increase [7] which has been related to statins.
In addition to CAD, aortic valve stenosis is associated
to endothelial damage and decreased EPC number and
function has been described in these patients [16]. A
proper EPC function may be essential for the favorable
outcome of surgical grafts [23]. Both in CABG and in
valve replacement surgery, EPCs are dramatically
released in response to surgical stress, although they
seem to be functionally impaired [17]. Restoration of a
proper EPC function in both surgical conditions may
prove a promising therapeutic strategy. Nevertheless, no
data were available about the comparative basal levels of
EPCs in the pre-surgical blood of CABG and valvular
replacement patients. In the present study we show that
the number of CD34+/CD144+ cells is decreased in the
pre-surgical blood of CABG patients, compared to valvu-
lar patients with angiographic absence of CAD. Both
cardiac surgery patients had a higher abundance of
CD34+/CD144+ cells compared to healthy controls. This
may possess a putative diagnostic and prognostic value.
Conclusions
This is the first study which demonstrates a relative EPC
depletion in the pre-surgical blood of patients
undergoing CABG compared to patients undergoing
valve replacement, where CAD was angiographically
demonstrated or ruled out, respectively. Given that
EPCs seem to play an important role in cardiac surgery
grafting, this finding may help to improve our under-
standing for the simulation of this reparatory mechan-
ism. The study of the underlying mechanisms of this
EPC depletion in CAD will be the subject of further
research efforts.
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